Cover Image
Market Research Report

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2018

Published by Global Markets Direct Product code 264085
Published Content info 179 Pages
Immediate Delivery Available
Price
Back to Top
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2018
Published: March 6, 2018 Content info: 179 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2018, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 1, 13, 8, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC10225IDB

Table of Contents

  • Table of Contents
  • Introduction
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Development
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AlfaSigma SpA, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athera Biotechnologies AB, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by BiogenCell Ltd, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co Ltd, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by LipimetiX Development Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Novartis AG, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Symic Biomedical Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by VESSL Therapeutics Ltd, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co Ltd, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma Inc, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2018 (Contd..1), H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2018 (Contd..2), H1 2018
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by Top 10 Targets, H1 2018
  • Number of Products by Stage and Top 10 Targets, H1 2018
  • Number of Products by Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Top 10 Molecule Types, H1 2018
  • Number of Products by Stage and Top 10 Molecule Types, H1 2018
Back to Top